Medigen vaccine data good but questions remain: Experts
06/11/2021 05:34 PM
CNA file photo
Taipei, June 11 (CNA) The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease. Data looks quite good, Academia Sinica academician Michael M.C. Lai (賴明詔), a reputed virologist and coronavirus researcher, told CNA on Thursday after Medigen announced that its vaccine candidate had shown no major safety concerns.
Lai said the published data showed the vaccine was able to produce sufficient neutralizing antibodies, and as long as there were antibodies, there should be protection, while also noting that its toxicity was low.